PlainRecalls
FDA Drug Critical Class I Ongoing

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.

Reported: September 27, 2023 Initiated: September 8, 2023 #D-1174-2023

Product Description

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.

Reason for Recall

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Details

Units Affected
1272 bottles
Distribution
Nationwide in the USA
Location
East Hanover, NJ

Frequently Asked Questions

What product was recalled?
SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.. Recalled by Novartis Pharmaceuticals Corp.. Units affected: 1272 bottles.
Why was this product recalled?
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 27, 2023. Severity: Critical. Recall number: D-1174-2023.